Hospital

A recent study shows that heart patients who learn to cope with stress in group therapy are nearly 2 times less anxious and depressed.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

The popularity of intermittent fasting, or time-restricted eating patterns, may not help control weight as well as other dieting methods.

OR-449 is being developed for both adult and pediatric patients with adrenocortical carcinoma, as well as other cancers known to express a high level of steroidogenic factor-1.

The impact of RSV includes serious financial challenges, strained relationships, and mental health concerns.

CAR T cell gel eliminated the residual tumor cells in almost all mouse models, allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.

Analysis includes 11 individuals who sat in ergonomic chairs for 8 hours and only got up at the recommended times.

Matt Gibbs, president of Capital Rx, to discusses alternative career paths for students, including independently owned PBMs.

The device features advancements to improve patient care, eliminating or reducing the risk of blood leakage around valve implants.

Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team.

Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements.

Carina Dolan, PharmD, BCOP, senior director for Clinical Oncology and Pharmaceutical Outcomes at Vizient Inc, discusses the highlights and big picture moving forward for hospitals and health-system pharmacies.

18F-FDG PET/CT detects approximately 73% of tumor lesions, while 68Ga-FAPI finds approximately 94%.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

This is the first indication for tucatinib that extends beyond the treatment of advanced unresectable or metastatic HER2-positive breast cancer.

Older patients received cancer treatment less frequently during the pandemic, as did patients covered by Medicaid.

Key trends such as consolidation create an opportunity for independent pharmacies with a community-based approach.

Data from a randomized clinical trial supports previous clinical findings on SGLT2 inhibitors and their ability to slow the progression of chronic kidney disease.

This week's episode features Amina Abubakar, PharmD, AAHIVP, CEO of Avant Pharmacy & Wellness Center and president of Avant Institute, who discusses her experience in the pharmacy industry and the communities she serves.

The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.

Soft tissue reconstruction solutions can leverage a patient’s natural healing response.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.

Research highlights that 6 doses of sublingual ketamine may be more effective than 3 doses, however both can ameliorate symptoms of anxiety and depression.

Molecular methods such as polymerase chain reaction show promise in monitoring the patient environment in hospitals and could help to provide reassurance prior to admission.

Individuals with higher caffeine levels were less likely to have liver fibrosis, while higher levels of non-caffeine coffee components were associated with reduced fatty liver index scores.

Analysis indicates 4 peptides had significant or nearly significant seropositivity, all of which were associated with membrane and spike proteins of SARS-COVID-2.

Study results shows that the use of a point-of-care tool and timely after care were essential to lowering the risk of hospitalization from cardiovascular disease within 30 days after acute HF.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.